CARDIFF ONCOLOGY, INC. Restructuring and Related Cost, Expected Cost
CARDIFF ONCOLOGY, INC. (CRDF) had Restructuring and Related Cost, Expected Cost of $2.00 million as of 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Notes
us-gaap:RestructuringAndRelatedCostExpectedCost1 · last filed 2017-11-09
- 2017-09-30: Restructuring and Related Cost, Expected Cost $2.00M.
- 2017-06-30: Restructuring and Related Cost, Expected Cost $2.00M.
- 2017-03-31: Restructuring and Related Cost, Expected Cost $2.00M.
| Period end | Restructuring and Related Cost, Expected Cost |
|---|---|
| 2017-09-30 | $2.00M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $2.00M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $2.00M 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |